|
Synonyms: BMS-986460 | BMS986460 | Example 5 [US20250188056]
Compound class:
Synthetic organic
Comment: Orevandrodeg (BMS-986460) is an orally bioavailable androgen receptor targeting PROTAC [1]. It engages the cereblon (CRBN) E3 ubiquitin ligase.
|
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| Orevandrodeg (BMS-986460) was progressed as a clinical candidate for the treatment of metastatic prostate cancer. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT06067841 | A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer | Phase 1 Interventional | Bristol-Myers Squibb | ||
| NCT06877702 | A Single-dose Study to Evaluate the Safety, Tolerability, Drug Levels, and Relative Biological Availability of Alternate Formulations of BMS-986460 in Healthy Adult Male Participants | Phase 1 Interventional | Bristol-Myers Squibb | ||